- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AbbVie Inc (ABBV)
Track today's live AbbVie (ABBV) share price, performance and key data on this page with our current NYSE:ABBV stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the AbbVie share price on the NYSE exchange. Use the dropdown to switch exchange for the ABBV share price, head to our technical summary section, which provides analysis on AbbVie share price buy/sell indicators using real-time data (or discuss the AbbVie (ABBV) stock price today with other investors in the AbbVie NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE:ABBV share price (ISIN: US00287Y1091) to enhance your trading decisions with our free investment tools and resources.
What Is the AbbVie Inc Share Price Today?
The AbbVie share price today is 250.88.
What Is the Stock Symbol for AbbVie Inc
The stock symbol (or 'ticker') for AbbVie Inc is "ABBV."
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NYSE:ABBV share price (ISIN: US00287Y1091) to enhance your trading decisions with our free investment tools and resources.
What Is the AbbVie Inc Share Price Today?
The AbbVie share price today is 250.88.
What Is the Stock Symbol for AbbVie Inc
The stock symbol (or 'ticker') for AbbVie Inc is "ABBV."
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
247.00
255.11
52 wk Range
189.79
267.47
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
247.00255.11
52 wk Range
189.79267.47
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.69%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.69%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABBV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
268.68
Upside
+7.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Why is AbbVie stock sliding today?- Investing.com
AbbVie Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
24 Buy
6 Hold
1 Sell
Ratings:
31 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 268.68
(+7.09% Upside)
AbbVie Inc SWOT Analysis
Pipeline Powerhouse | Explore AbbVie's robust drug pipeline, featuring promising candidates in late-stage development across multiple therapeutic areas, poised to drive future growth |
Humira's Heir Apparent | Discover how Skyrizi and Rinvoq are exceeding expectations, with combined revenue projections surpassing $31 billion by 2027, offsetting Humira's decline |
Strategic Acquisitions | Learn about AbbVie's recent acquisitions of ImmunoGen and Cerevel, bolstering its oncology and neuroscience portfolios and diversifying revenue streams |
Analyst Optimism | Delve into analyst perspectives, with price targets ranging from $205 to $240, reflecting confidence in AbbVie's ability to navigate challenges and capitalize on opportunities |
AbbVie Inc Earnings Call Summary for Q2/2026
- AbbVie Q2 revenue reached $16.99B, beating estimates by $220M, but adjusted EPS of $3.65 missed forecasts by $0.06, causing shares to drop 2.19%.
- Company raised full-year 2026 revenue guidance by $300M to $67.6B; adjusted EPS guidance set at $13.87-$14.07, reflecting Apogee acquisition dilution.
- SKYRIZI sales surged 24% to $5.5B and RINVOQ rose 23.7% to $2.5B, offsetting HUMIRA's 36.1% decline to $756M amid biosimilar competition.
- Q3 guidance projects revenue of $17.2B and adjusted EPS of $3.84-$3.88; Apogee Therapeutics acquisition expected to close in Q3, adding $0.14 EPS dilution.
- Management highlighted strong pipeline progress including potential SKYRIZI subcutaneous approval for Crohn's disease and RINVOQ approvals for vitiligo.
Last Updated: 31/07/2026, 15:26
Read Full TranscriptEarnings
Latest Release
31/07/2026
EPS / Forecast
3.65 / 3.71
Revenue / Forecast
16.99B / 16.77B
Compare ABBV to Peers and Sector
Metrics to compare | ABBV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABBVPeersSector | |
|---|---|---|---|---|
P/E Ratio | 124.1x | 19.7x | −0.3x | |
PEG Ratio | −9.55 | −0.37 | 0.00 | |
Price/Book | −67.0x | 1.2x | 2.6x | |
Price / LTM Sales | 7.1x | 2.5x | 3.0x | |
Upside (Analyst Target) | 7.6% | 27.2% | 56.6% | |
Fair Value Upside | Unlock | 10.6% | 10.2% | Unlock |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the AbbVie (NYSE: ABBV) Share Price Today?
The AbbVie stock price today is 250.88 USD.
What Stock Exchange Does AbbVie (ABBV) Trade On?
AbbVie is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for AbbVie?
The stock symbol (also called a 'ticker') for AbbVie is "ABBV."
Does AbbVie Pay Dividends? What’s The Current ABBV Dividend Yield?
Yes, ABBV Pays Dividends to its Shareholders. The current AbbVie dividend yield is 2.69%.
What Is the Current AbbVie Market Capitalisation?
As of today, AbbVie (NYSE: ABBV) market cap is 444.72B USD.
What Is AbbVie's (ABBV) Earnings Per Share (TTM)?
The AbbVie EPS is currently 2.03 (Trailing Twelve Months).
When Is the Next AbbVie Earnings Date?
AbbVie's next earnings report will be released on 31/07/2026.
Is ABBV a Buy or Sell From a Technical Analyst Perspective?
Based on today's AbbVie moving averages and other technical indicators, the daily buy/sell signal for ABBV stock is Neutral.
How Many Times Has AbbVie Stock Split?
AbbVie has split 0 times. (See the ABBV stock split history page for full effective split date and price information.)
How Many Employees Does AbbVie Have?
AbbVie has 57000 employees, based on their latest Companies House report.
What is the current trading status of AbbVie (NYSE: ABBV)?
As of 31/07/2026, AbbVie (ABBV) is trading at a share price of 250.88 USD, with a previous close of 257.41 USD. The stock has fluctuated within a day range of 247.00 USD to 255.11 USD, while its 52-week range spans from 189.79 USD to 267.47 USD.
What Is AbbVie (ABBV) Price Target According to Analysts?
The average 12-month price target for AbbVie is 268.68 USD, with a high estimate of 328 USD and a low estimate of 200 USD. 24 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +7.09% Upside potential.
What Is the ABBV Premarket Price?
ABBV's last pre-market stock price is 247.34 USD. The pre-market share volume is 69,030.00, and the stock has decreased by -10.07, or -3.91%.
What Is the ABBV After Hours Price?
ABBV's last after hours stock price is 250.94 USD, the stock has decreased by -0.02, or -0.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.